“I’m Not Gonna Pull the Rug out from under You”: Patient-Provider Communication about Opioid Tapering by Matthias, Marianne S. et al.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 “I’m Not Gonna Pull the Rug out from under You”: Patient-Provider Communication about Opioid 
Tapering 
Marianne S. Matthias, Ph.D.,
1-4
 Nicole L. Johnson, M.A.,
3
 Cleveland G. Shields, Ph.D.,
5
 Matthew J. Bair, 
M.D., M.S.,
1,2,4
 Palmer MacKie, M.D., M.S.,
1
 Monica Huffman, B.S.,
2
 Stewart C. Alexander, Ph.D.
6 
1
 Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 
2
 Regenstrief Institute, Inc., Indianapolis, IN 
3 Department of Communication Studies, Indiana University-Purdue University Indianapolis, 
Indianapolis, IN 
4 Center for Health Information and Communication, Roudebush Veterans Affairs Medical Center, 
Indianapolis, IN 
5
 Department of Human Development & Family Studies, Regenstrief Center for Healthcare Engineering, 
Purdue Center for Cancer Research, Purdue University, West Lafayette, IN 
6
 Department of Consumer Science, Purdue University, West Lafayette, IN 
Running Title: Communication about Opioid Tapering 
Corresponding Author: Dr. Marianne Matthias, 1481 W. 10
th
 St (11H), Indianapolis, IN 46202 
Email: mmatthia@iupui.edu 
Phone: 317 278.3154 
Word count (abstract): 192 
Word count (main text): 5679 
Number of references: 34 
Number of tables: 1 
Number of appendices: 0 
Key Words: chronic pain, opioids, opioid tapering, patient-provider communication, patient-centered 
care 
Disclosures: This research was funded by the National Institute on Drug Abuse of the National Institute 
of Health under award number 1R21DA037384-01A1. The content is solely the responsibility of the 
authors and does not necessarily represent the official views of the National Institutes of Health. The 
authors declare no conflicts of interest. 
The authors would like to thank Rachel Gruber, M.S., for assistance with manuscript preparation and 
formatting. 
_________________________________________________________________________________
 
This is the author's manuscript of the article published in final edited form as: 
Matthias, M. S., Johnson, N. L., Shields, C. G., Bair, M. J., MacKie, P., Huffman, M., & Alexander, S. C. 
(2017). “I’m Not Gonna Pull the Rug out from under You”: Patient-Provider Communication about Opioid 
Tapering. The Journal of Pain. https://doi.org/10.1016/j.jpain.2017.06.008
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
Abstract 
In response to increases in harms associated with prescription opioids, opioid prescribing has come 
under greater scrutiny, leading many healthcare organizations and providers to consider or mandate 
opioid dose reductions (tapering) for patients with chronic pain. Communicating about tapering can be 
difficult, particularly for patients on long-term opioids who perceive benefits and are using their 
medications as prescribed. Given the importance of effective patient-provider communication for pain 
management and recent health system-level initiatives and provider practices to taper opioids, this 
study used qualitative methods to understand communication processes related to opioid tapering, to 
identify best practices and opportunities for improvement. Up to 3 clinic visits per patient were audio-
recorded, and individual interviews were conducted with patients and their providers. Four major 
themes emerged: 1) Explaining—Patients needed to understand individualized reasons for tapering, 
beyond general, population-level concerns such as addiction potential; 2) Negotiating—Patients needed 
to have input, even if it was simply the rate of tapering; 3) Managing difficult conversations—When 
patients and providers did not reach a shared understanding, difficulties and misunderstandings arose; 
4) Non-abandonment—Patients needed to know that their providers would not abandon them 
throughout the tapering process.  
Perspective: Although opioid tapering can be challenging, helping patients to understand individualized 
reasons for tapering, encouraging patients to have input into the process, and assuring patients they 
would not be abandoned all appear to facilitate optimal communication about tapering.  
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INTRODUCTION 
Chronic pain affects approximately 100 million Americans and is associated with deleterious 
outcomes such as reduced quality of life, depression, and anxiety.
7
 In recent years, use of opioid 
analgesics to treat chronic pain has increased dramatically. From 2007 to 2012, total opioid prescriptions 
increased almost 12%, with the greatest increases in physical medicine, pain medicine, family practice, 
internal medicine, and general practice.
20
 These increases have been paralleled by increases in opioid-
related harms—in particular deaths and abuse.
19, 28, 29
  In response, numerous organizations and federal 
agencies, including the American Pain Society/American Academy of Pain Medicine,
7
 the Department of 
Veterans Affairs/Department of Defense,
33
 and the Centers for Disease Control,
11
 have developed 
guidelines for opioid prescribing, and states and institutions have developed their own laws and policies 
governing opioid prescribing.  
 Increased scrutiny of opioid prescribing for chronic pain and lack of evidence supporting long-
term efficacy of opioid therapy
27
 has led providers and healthcare organizations to consider or mandate 
opioid dose reduction (tapering) for patients with chronic pain.
1,25,15,32
 This mandate creates 
communication challenges between patients and providers, particularly for patients who have been 
taking long-term opioids, receiving benefit from them, and are using them as prescribed. These 
challenges may be exacerbated by the inherent difficulties identified in the literature with respect to 
communicating about pain and its treatment.
24,31
 Given the importance of effective patient-provider 
communication for pain management,
26,23
 and  recent opioid tapering initiatives, it is essential to 
understand the communicative processes surrounding tapering, both to identify best practices and 
opportunities to improve the process (and ultimately, outcomes) for both patients and providers.  
 To examine communication about opioid tapering in depth, we conducted a qualitative analysis 
of audio-recorded primary care clinic visits with patients taking opioids for chronic pain, and then 
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conducted in-depth interviews with patients and their primary care providers (PCPs) to identify 
communicative challenges and best practices associated with opioid tapering.  
METHODS 
Study Design. These data are part of a larger study focused on understanding communication 
about opioid management. The study involved audio-recording up to 3 primary care appointments per 
patient with patients prescribed an opioid for chronic musculoskeletal pain. Patients and their PCPs also 
participated in individual qualitative interviews. 
Setting and Participants. The study was conducted in 4 of the 9 primary care clinics at an 
academic, safety-net hospital serving primarily low-income patients. Procedures were approved by the 
local institutional review board, and all participants signed an informed consent; patients also signed a 
HIPAA (Health Insurance Portability and Accountability Act) authorization to allow access to protected 
health information. 
Eligibility. PCPs were eligible to participate if they practiced in one of the medical center’s 
primary care clinics and had patients with chronic pain for whom they were prescribing opioids. Patients 
were eligible if they met the following criteria: 1) at least 18 years of age; 2) patient of participating PCP; 
3) had chronic musculoskeletal pain (defined by ICD-9 codes: 715, 719, 721, 722, 723, 724, 726, 729.0, 
729.1, 729.3, 729.5, 738.4, 738.5); 4) currently taking a prescribed opioid for pain; 5) speaks English with 
PCP. 
Recruitment. We mailed a letter explaining the study to patients who met inclusion criteria, and 
the project coordinator followed up with a phone call. If patients agreed to participate, study staff met 
patients in the clinic waiting room prior to their next PCP appointment, further explained the study, 
answered questions, and obtained informed consent.  
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Data Collection Procedures. Data collection occurred over 20 months, from 2015-2017, until 
theoretical saturation was reached (i.e., additional data no longer led to new theoretical insights or 
revealed new properties in themes identified during analysis
5
). Data sources consisted of 1) audio 
recordings of primary care visits (up to 3 per patient); 2) patient qualitative interviews; 3) PCP qualitative 
interviews. For clinic recordings, an audio recorder was placed in the exam room, with the research staff 
member waiting outside the room. Recorders were collected at the conclusion of each visit and 
arrangements were made for contacting the patient about recording his/her next PCP visit. After 
completing at least two PCP visits, the patient’s qualitative interview was scheduled. PCPs were 
interviewed after all or most of their patients’ visits had been recorded, based on availability. Part of the 
interview protocol for patients and PCPs included playing a portion of a recorded clinic visit pertaining to 
pain and/or opioid management, to elicit participants’ perceptions of the communication in the visit. All 
interviews were one-on-one, face-to-face, and audio-recorded. All audio recordings (clinic visits and 
interviews) were transcribed, de-identified, and checked for accuracy. 
Interviews. The project coordinator (MH), an experienced qualitative interviewer, conducted all 
interviews. We asked patients and PCPs about the patient-provider relationship, pain/opioid 
management, opioid monitoring practices, and policies/laws governing opioid prescribing.  
Data Analysis. A total of 95 clinic visits (up to 3 per patient) and 31 (9 PCP, 22 patient) 
interviews were recorded and analyzed. The first author, working with two other experienced 
qualitative data analysts (NJ, MH), led data analysis, which consisted of an inductive approach using the 
method of constant comparison.
5,21
 This is an iterative process with two broad phases: open coding and 
focused coding.
5,21
 During open coding, team members read all transcripts analyzing them for common 
and recurrent themes. This step elucidated aspects of opioid management and tapering. During focused 
coding, analysts developed additional conceptual domains by describing comparisons between themes, 
within and between transcripts. 
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 Throughout this process, procedures established in the literature on qualitative methods were 
employed to ensure rigor and validity. These procedures included practicing reflexivity (continually 
questioning interpretations, seeking answers in the data to verify or challenge interpretations, becoming 
aware of one’s own preconceptions and biases), depth of description (seeking out the rich, particular 
details of participants’ words), and searching for alternative explanations or interpretations of the 
data.
18,20-22
 All authors participated in final interpretations of the data. 
RESULTS 
 Nine PCPs and 37 of their patients participated. PCPs ranged in age from 30-62 years. Seven 
PCPs were White; one was Black, and one was Asian. Eight were female, and all PCPs were non-Hispanic. 
Patients were aged 22-74 years (M=58; SD=10.4). Seventeen patients were Black, 15 were White, 1 was 
American Indian/Alaskan Native, and the remainder did not provide race data. All patients were non-
Hispanic; 12 were male. See Table for demographics. One patient withdrew from the study after the first 
clinic visit, citing lack of time.  
Notably, this study’s purpose was to understand communication about opioid management for 
chronic pain, and tapering appeared as an emergent theme. Four themes revealed different aspects of 
patient-provider communication that appeared central to the tapering process: 1) explaining reasons for 
tapering; 2) negotiating the tapering plan; 3) managing difficult conversations; and 4) assuring patients 
that they will not be abandoned. 
Explaining Reasons for Tapering 
Both patients and PCPs emphasized the need for understanding individualized reasons for 
tapering, especially if patients were using their opioids as prescribed. In several clinic visits, PCPs 
explained in detail reasons for tapering, including risks and side effects of opioids. For example, the 
following PCP provided a long explanation of why she was tapering this patient, including emphasizing 
that it was not because of concerns of abuse or diversion. A short excerpt is below: 
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I don't have a concern with you abusing or selling them. I mean, we know each other 
and we know that's not an issue. The issue is that over time they stop working… the 
higher and higher doses of pain medications people are on, it can cause side effects, bad 
constipation, it can cause depression, it can cause decrease in your drive to breathe, and 
these are in people who are not trying to do anything wrong, they just want relief. 
(Clinic: PCP3, Pt3) 
However, as the following clinic excerpt illustrates, patients and PCPs did not always agree on 
the need to taper:   
PCP:   So what we were planning on doing is continuing to wean you… 
Patient:   And my pain gets worse and worse and worse. 
PCP:   But the oxycodone, that wasn't the thing that… 
Patient:   They were helping me to move around, get more like it wasn't even so stiff and 
achy. 
PCP:   But it's just, it's not safe. It is just not safe. 
Patient:   Ok I understand that too, but I don't think it is fair to me and my pain. 
PCP:   We can try some stuff today, but an opiate or narcotic pain medication is not a 
safe option for you right now. (Clinic: Pt5, PCP2) 
Frequently patients told us that they did not understand why their opioid doses were being 
reduced. Some patients said they had no discussions with their PCPs about reasons for tapering. Others 
described having conversations with their providers that addressed general reasons for tapering but did 
not apply to them specifically (e.g., addiction is a potential risk). In fact, many patients told us that they 
understood global risks such as addiction potential, but they did not believe that these risks applied to 
them personally, either because they were genuinely in pain, or because they were not engaging in 
aberrant behaviors (e.g. asking for early refills, taking more than prescribed, or losing their 
prescriptions). For example, one patient said, 
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She had me down from 10 to 5 [mg], and I didn’t understand because I was still in the 
same amount of pain. I asked her and she said that a lot of people was OD’ing on pain 
medication and getting addicted…but I told her I was in a lot of pain, and this was not 
addiction…because I do be in a lot of pain (Interview: Pt6). 
Other patients expressed similar sentiments:  
I’m not taking a high dose, not asking for more…it’s not like I go to them every 6 months 
and say hey, I need more. I don’t do that…I know what they say is correct for some 
people…but that’s not gonna work for me (Interview: Pt2). 
[My doctor] treated me like I was a druggie or something, and I don’t take anything 
that’s not prescribed or more than is prescribed. I’ve been on [the opioids] for years and 
years, and what [another doctor] prescribed me, I wasn’t even taking all of it. [Now the 
dose] is cut to less than half of what I used to take (Interview: Pt20). 
PCPs recognized that patients often have difficulty understanding how concerns about opioid risks 
apply to them: 
The argument about narcotics is sometimes difficult because patients look from their 
perspective. They are looking at it from an N of 1, right? And so they’re thinking, 
especially because we have a lot of patients who’ve been on narcotics for years, “So I’ve 
taken this medicine, I’ve been fine for 10 years. It works for me…why in the world would 
you change it?” And from my point of view, you know, we’re looking at millions of 
people and data (Interview: PCP5). 
Another PCP stated more bluntly, 
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Everybody thinks they’re unique and they’re not gonna overdose, and they’re not 
addicted, and they never did anything wrong, and they need their medicine, and they’ve 
never had any of those side effects, and [the opioid] helps them (Interview: PCP7). 
In response to this disconnect between knowledge about opioid risks and its application to 
individual patients, some PCPs successfully tailored their messages about opioid tapering to their 
patients’ individual circumstances. For example, the following PCP described how she helped a patient 
with pulmonary disease better understand why she was reducing her opioids:   
We were able to very directly talk about the [opioid] medication’s effects potentially on 
her respiratory system. So that was very clear to her. [I said], “Listen, you have a 
decreased respiratory drive. You are on oxygen. We don't want anything else to 
suppress that.”  So I think having that tangible, kind of helped her to buy into it, instead 
of abstractly talking. She really can see, I'm on oxygen and I don’t really breathe well. 
And then once we got her to two a day and she feels good, then she can, again, kind of 
buy into that (Interview: PCP2). 
 The following PCP took a similar approach in clinic with a patient by explaining how aging played 
an important role in the need to reduce opioids: 
Just something to think about because it's gonna happen at some point. [The opioid] is 
gonna build up in your system and cause you problems, so we might as well get ahead 
of it. I've been through this with other folks. You know you get older. You're a few years 
older than you were before, and the organs just don't work as quickly to break it down, 
and so you're still left in pain. It's tricky. It's really tricky 'cause you've still got the pain 
but we have to attack that in different ways because you've got this drug on board that 
will eventually likely cause you problems. (Clinic: PCP1, Pt7) 
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Negotiating the Tapering Plan 
While helping patients understand the individual reasons that tapering was important, patient 
input in the tapering process also emerged as an important theme. Both patients and PCPs described a 
desire for patients to be given options and thereby have some control over the tapering process. 
Sometimes patients and their PCPs were able to successfully negotiate tapering. Other times they 
believed the other person was not listening; thus, communication broke down. 
One patient described a process of successful negotiation with her provider: 
She put me down to 2 ½ [pills/day]. Then she said, okay, we’ll go down to half a pill. I 
told her I didn’t think that just two a day would do it, and she said okay, we’ll try 2 ½, 
are you agreeable with that? I said that’s fine. I mean, we can discuss stuff. It doesn’t 
have to be a disagreement because we can talk about it. It’s not an argument. We’re 
two adults having a conversation, figuring out what to do (Interview: Pt3). 
This patient’s PCP described a similar process of collaboration: 
I try to give them options. We could go down this month from four a day to three a day, 
or to three and a half a day, or we can switch from oxycodone to hydrocodone. So I try 
and give them different options and I think that has helped me actually get people more 
on board. These are the ways that we can do it together and then, I have really listened 
to people when I've been weaning a little bit and if they say, this is not working I'm in a 
lot of pain, I've gone back up for a little while and tried to figure out a different way to 
bring them down (Interview: PCP3). 
 In this patient’s clinic visit, we see the provider giving the patient options: 
   Provider: Yeah, so you have the 7.5 [mg]. You’re on the higher doses of them, so in 
trying to cut back, we could do a couple of things. We could cut back the numbers, the 
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amounts that you get, or we could cut back how much is in each pill. So you have 7.5 
now, so we could try to go to 5’s. What I’m thinking now is, let’s just do this really 
slowly. Why don’t you do one in the morning. Let’s keep the same 7.5’s that you have 
now. 
   Patient: Yeah. 
   Provider: This is my suggestion. You do one in the morning, half in the afternoon, and 
one at night. Do you think you would be able to do that? It’s not such a big change. 
   Patient: Yeah, I think so. (Clinic Visit: Pt3, PCP3) 
 Another clinic excerpt with the same provider and a different patient also shows this provider’s 
efforts to involve the patient: 
   Provider: I want to make sure that you’re on board with this too. 
   Patient: Yeah, I’m on. I’ll do what I can do…I never liked to take medicine, period. 
   Provider: I know. (Clinic Visit: Pt9, PCP3) 
 Not all patients felt involved in the process. One patient believed that her doctors were conferring 
with each other and making decisions without her: “I would like for [my doctor] to listen to me rather 
than listen to what my rheumatologist says to her, and how they communicate without me” (Interview: 
Pt17). Another patient believed she had not been told her opioid dose was being lowered: “He had 
lowered it and I didn’t even realize it…he didn’t even tell me it was getting lowered again. I wondered 
why I ran out even earlier than what I normally did…Nobody is telling me that.” This patient went on to 
say of her doctor, “I just don’t feel that he’s understanding…he don’t seem to care what I’m saying, 
because he’s lowering it down anyway, even though I’ve told him…that I didn’t agree with it being 
lowered.” (Interview: Pt2) 
 Another patient described trying to be involved, but that his doctor would not listen: 
Patient:  I can’t hardly walk in the mornings. I think [opioids] help with spasms. 
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Interviewer:  Did you tell him that? 
Patient:  Yeah, but he don’t want to…I couldn’t get him to look me in the eye when 
I was trying to explain…He didn’t even look up. He just wrote on the 
paper. (Interview: Pt20) 
It was not only patients who felt they were not being heard. Providers, too, described trying to 
explain tapering and discuss options with patients, often without success:  
It’s really bad because they have one specific thing that they want and they aren’t really 
listening, most of them, to the other options. Yet I’ve got the law, hospital policy, my 
own good judgment, and it’s saying I can’t just—I want to try and help you get better, 
but only under certain circumstances (Interview: PCP7). 
Managing Difficult Conversations 
As the above themes suggest, conveying understanding and negotiating about tapering were 
not always successful, and the result was conversations that could be contentious and frustrating. The 
following clinic visit involved a lengthy discussion about opioid tapering, including arguments and 
threats to obtain opioids elsewhere: 
Patient:   But, like it is not fair. 
PCP:   Well, but my goal for you is to keep you safe and to also make sure that I'm not 
actually hurting you by giving you the medicines that I'm doing. 
Patient:   It's not because you give them to me and you feel guilty for yourself? 
PCP:   Oh what?  Hang on, say it again. 
Patient:  You feel guilty about prescribing them to me because of your feelings about 
them? 
PCP:   It's not a matter of guilt or a matter of my feelings about them. It is a matter of 
actually facts. We know that these medications can be harmful. It is not just my 
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opinion. We know that these medications can actually potentially even worsen 
pain and worsen depression. We know that they can be used as a way to hurt 
yourself. 
Later in the visit, the following exchange took place: 
Patient:   I was just going to tell you to be honest with you. If I can't get my own script, 
then they are going to make me go out and ask for people, do you have any 
pain medicine?  You know?  I don't want to go that far.  
PCP:   No and . . . 
Patient:   But if I have to I will. I'm in so much pain…Because you cut me, all I got was 56 
[pills/month]. Oh well, I'm just saying oh ok we will have to do this. (Clinic 
Visit: Pt5, PCP2) 
Not surprisingly, conversations such as the one above can have an effect on PCPs. One PCP 
expressed her frustration with an elderly patient who was beginning to experience falls and show 
symptoms of confusion: 
Oh, my gosh, 45 minutes every visit to explain to her the whole concept of first do no 
harm and what harm means for her and what harm has already--I literally read at our 
last visit, another 45 minute visit, I literally read the geriatric consult…She has called my 
nurse at least three times, and that's a half-hour discussion every single time. I clench 
my shoulders, I feel tension in my spine and neck when I go in to see her. It’s this battle, 
and we both want what’s best for her. Oh my goodness, it keeps me up at night 
(Interview, PCP1). 
 For patients who are using their opioids as prescribed and believe they are doing well, 
conversations about tapering can be especially difficult, since it is not usual practice to discontinue a 
medication that appears beneficial. The same PCP as above explained:   
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It automatically sets up this punitive conversation when you say, you know you were 
doing great, [but] I'm going to cut off your medicines. Because we don't do that in any 
other disease. We don't do that in hypertension. We don't do that with insulin…So this 
is what people are coming in with, and it's like if I’m doing great, she's going to keep 
giving my medicines. And that's a hard conversation (Interview: PCP1). 
 Although not all conversations were overtly contentious, situations when PCPs had trouble 
justifying, even to themselves, the reasons to taper a particular patient sometimes exacerbated the 
difficulty of these conversations. The following PCP described her own internal conflict about tapering 
an 85-year old patient for whom she was not sure tapering was appropriate:  
Sometimes I have to just check myself in terms of, you know, is this my issue?  Is this 
just that I don't like the numbers? Because, there's data and we know that [opioids are] 
not good for elderly, but then people are also individuals…This guy seems to be thriving. 
And so maybe he's one of the people I leave alone…But then I see him and I talk to him, 
and I'm like, I don't know, maybe [tapering] is the right thing. I think it’s more of an 
internal conflict than a conflict when he's in the room. There's not arguing. It’s more of, I 
sort of ruminate on it (Interview: PCP 3). 
PCPs also described conversations that went well. A typical example is the PCP who said, “The 
woman I had to wean, she accepted it. She said, ‘you know, I don’t think I did anything wrong. I used my 
own medication, but I understand what you have to do, and I think I’ll be okay without them’. And that 
was kind of it.” (Interview: PCP3) 
One PCP actually described surprise when conversations go well: “I’ve been pleasantly surprised 
when people don’t get angry, and they say, ‘Well, I guess that’s a reasonable place to start’. And I’m a 
little bit bowled over because there were years when I would just get beat up.” (Interview, PCP9) 
Similarly, this PCP explained that opioid tapering conversations have become easier:  
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Sadly I guess I've gotten rather... good at [conversations about opioid tapering]…I'm 
comfortable with it. I mean it's never fun. I do kind of plan ahead--this is what we're 
gonna have to do today and how can I set the stage. I just know that it works better if 
you know you got your plan in mind and basically can kind of follow it through. And 
you've got a relationship (Interview: PCP7). 
Assuring Patients that They will not be Abandoned 
An important part of productive opioid tapering conversations, both for patients and providers, was 
ensuring that patients did not feel abandoned during tapering. As PCP 7 said above, the relationship is 
an important factor in tapering discussions. PCPs frequently reassured patients that they would be with 
them through the entire tapering process, and sometimes even told patients that if the pain became 
intolerable, they could discuss increasing the opioid dose again for a time. This seemed to provide an 
important safety net for patients. For example, one patient said, “I knew she wasn’t just going to take 
me completely off of [the opioids] because I would be miserable…She just said, ‘We’ll try this, but if you 
need to go back to where you were, I’ll do that’.” (Interview: Pt20) 
PCPs frequently described reassuring patients that they would not experience tapering alone: 
[Patients sometimes say], I'm not sure I believe this is gonna work…That's the vibes that 
they're giving. And I just try and reassure them that I hear them, how bad the pain is, 
and…what we do have to offer, and some kind of hope, and try and you know I want to 
work with you... and…If I've been able to build some rapport by really listening and 
asking lots of good questions and trying to be empathetic, then often they're [willing to] 
give it a chance…Most of these people I’ve been taking care of for a long time, so there’s 
at least that relationship, and they know I’m not going to cut them off (Interview: PCP7). 
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Another PCP described a conversation in which she relied on the long relationship she has had with the 
patient:  
She was nervous about [tapering], and I said this is a trial, you know, I'm not leaving, I'm 
not going anywhere. You know I'm with you. We've been together a long time, so I'm 
not going to disappear on you (Interview: PCP1). 
These sentiments were illustrated in clinic excerpts, such as the following when a patient’s PCP said, 
The hope would be next time to be done [tapering]. So, the hope is that this is your last 
prescription. Now, I'm not gonna leave you, you know, out to, what is it?  Out to dry…I 
forgot the expression. So, you know, work with me and if things aren't working, then we 
can revisit that, okay? (Clinic: PCP3, Pt9) 
More bluntly, one PCP reassured her patient in clinic, “I’m not gonna pull the rug out from under you. 
It’s not gonna happen, okay? Not gonna happen.” (Clinic: PCP1, Pt7) 
 
DISCUSSION 
  In response to widespread concerns about opioid-related harms, tapering has become common 
practice; however, despite the surge in tapering, we know little about how patients and their providers 
communicate about this process. Given that pain and opioid management are communicative activities 
and this communication is sometimes challenging,
22-24,31
it is critical to learn more about how tapering 
occurs. These lessons learned will help to inform future clinical communication about tapering, to 
optimize patients’ understanding of and experiences with tapering, and to avoid unintended negative 
consequences. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
In recorded clinic visits and individual interviews with patients and PCPs, four themes emerged 
related to opioid tapering: 1) Explaining reasons for tapering; 2) Negotiating the tapering plan; 3) 
Managing difficult conversations; and 4) Assuring patients that they will not be abandoned. Both 
patients and PCPs recognized that patients needed to understand reasons for having tapering 
discussions. Patients acknowledged generally that opioids could be harmful and that some people 
misused them, but often did not see how this was applicable to them, because they legitimately had 
pain and were taking their medications as prescribed. Previous research has corroborated the notion 
that patients generally understand the risks of opioids, but most do not think that these risks apply to 
them.
12
 PCPs acknowledged this gap in understanding, noting that patients only have their own 
experiences for perspective (“an N of 1”). These findings point to potential benefits of shifting the 
conversation about opioid tapering from the current opioid crisis, which is abstract and distant for 
patients, to a patient’s own unique medical history and the particular risks that opioids can pose based 
on this history. Future research should seek to identify optimal ways for PCPs to frame messages about 
opioid tapering.  Educational efforts should seek to help PCPs individualize  opioid tapering to facilitate 
patients’ understanding of tapering as an effort to protect their health, and not as punishment.  
Involving patients in tapering was critical, both to patients and to PCPs. In an environment of 
state and institutionally mandated tapering, patients and providers often have little control over 
whether tapering happens. Nonetheless, patients expressed a desire to have input into these decisions, 
and many providers agreed and were willing to work with patients on details such as the rate of 
tapering. Unsurprisingly, breakdowns in communication still occurred. Patients described trying 
unsuccessfully to negotiate their tapering, and PCPs described patients who persistently resisted 
tapering efforts. Difficult interactions about pain are well-documented,
2,10,12,18,24,31,34
and widespread 
opioid tapering is likely to place additional strains on already difficult patient-provider relationships.  
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 When communication broke down, either because of disagreements on the tapering plan, lack 
of understanding about tapering, or other reasons, this often led to difficult conversations in which 
patients argued, or even threatened to obtain their opioids illegally. Some PCPs described the emotional 
toll of these conversations. Further exacerbating this difficulty, PCPs were not always convinced that 
opioid tapering was best for certain patients. Although this skepticism emerged in interviews, it did not 
manifest in clinical communication in this study. It is unclear why this was the case; one possible 
explanation is that institutional pressure for overall reductions in opioid doses superseded PCPs’ doubts, 
leading them to remain silent.  PCPs have previously described pain management as challenging.
10,24
 
Breakdowns in communication about tapering can exacerbate these challenges, particularly  when PCPs 
themselves are unconvinced that tapering is appropriate for some patients. Unvoiced provider 
skepticism about opioid tapering for particular patients, and how providers approach this skepticism, is 
an important area for further research. Assuring patients that their PCPs would not abandon them 
during opioid tapering was identified as critical, by both patients and PCPs.  Beyond the general, abstract 
concept of “trust” that is often discussed, patients and providers pointed to non-abandonment as key 
for productive communication about opioid tapering. Patients needed to know that their providers were 
not going to reduce their opioids and then disappear. PCPs were acutely aware of this need and 
repeatedly responded with reassurances that they would not abandon their patients.  Some PCPs even 
expressed a willingness to increase an opioid dose temporarily if a patient was having difficulty adjusting 
to a lower dose. This notion of non-abandonment expands on the important role of the patient-provider 
relationship in chronic pain care.
24,31
 Strong relationships may be especially valuable when difficult 
decisions about opioid treatment are made. For example, when doctors demonstrated genuine concern 
for their patients’ health and wellbeing, patients with chronic pain seemed more willing to accept 
decisions to limit or deny opioids.22 In a recent study involving interviews with patients being tapered off 
of opioids, Frank and colleagues13 found that patients believed having a trusted physician was essential. 
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Studies have shown that when patients and their PCPs have similar concerns about opioids, they can 
approach these concerns collaboratively.
4,16,23 
Collaboration and trust  are especially important as non-
opioid treatments are explored and as patients face fears of opioid withdrawal or uncontrolled pain. 
Indeed, in Frank and colleagues’
13
 interviews, patients revealed that withdrawal and uncontrolled pain 
were major barriers to opioid tapering. Further corroborating  the importance of provider support 
during opioid tapering, a recent pilot study found that patients randomized to a taper support 
intervention involving psychiatric consultation and weekly meetings with a physician assistant showed 
greater improvement on pain interference, pain self-efficacy, and perceived opioid problems, than 
control patients.
30
 Support, further elaborated as non-abandonment in the current study, appears to be 
a critical element of communication about opioid tapering.  
  
  Findings from this study add to the small but growing body of research revealing how patients 
and providers experience opioid tapering. In Frank and colleagues’
13
 recent study involving interviews 
with patients at various stages of tapering,  patients noted that their current pain was more urgent than 
potential future risks of opioids, expressed skepticism about the efficacy of non-opioid analgesics and 
fear of withdrawal, and described the central role of social support during tapering. The current study 
illuminates the communicative processes surrounding opioid tapering, exploring both patients’ and 
PCPs’ perspectives, as well as actual clinical communication. Through these multiple data sources, the 
patient-provider relationship during tapering emerges as fundamental. Indeed, the current study not 
only underscores the centrality of this relationship, but illuminates critical aspects of this relationship 
that appear important to patients and providers during tapering. Providers have pivotal roles in helping 
patients to understand why they are being tapered, giving them input into the process, and assuring 
them that they will not be abandoned while their doses are being reduced.  
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  This study has some limitations. Although theoretical saturation was reached, a larger sample 
might have facilitated a fuller range of perspectives, particularly from PCPs. Some PCPs may have 
declined to participate in the study because of their views or approaches toward opioid tapering; 
consequently, we may have missed some aspects of clinical communication and perspectives related to 
opioid tapering. In addition, we did not assess dose, type, or duration of opioid treatment, or history of 
substance use disorder, all of which might influence communication about tapering. Finally, this study 
took place in the primary care clinics of one safety net hospital system; results should be corroborated 
in other settings.  
  This study has a number of strengths. Qualitative methods enable the capture of rich, particular 
details of participant experiences that may not be available through other methods.
6
 In addition, 
because  interview accounts by themselves are subject to recall bias and are shaped by participants’ 
own experiences and perspectives, combining interviews of both patients and providers with analysis of 
actual clinical communication allows for the fullest exploration of communication related to opioid 
tapering, providing insights from multiple perspectives.  
 Communication about chronic pain and its treatment is challenging, particularly when opioids 
are involved. Clearly, these communicative challenges can be exacerbated when patients are being 
tapered down or off opioids, oftentimes against their wishes. The current study highlights some 
important clinical implications as more patients experience tapering. Specifically, if clinicians tailor their 
messages to help each patient understand why tapering may be beneficial to them, based on their own 
unique circumstances and medical history, conversations about tapering could be more productive. In 
addition, our findings indicate that encouraging patients to have input into the tapering process, even if 
it is simply the rate of tapering, can  help patients feel as if they have some control over their treatment. 
Finally, while the centrality of the patient-provider relationship in pain management is recognized, the 
specific notion of non-abandonment emerged as critically important to both patients and providers. 
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Patients experienced tapering more positively when they felt assured that their providers would remain 
with them through the entire process. 
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Demographic  
Variable 
  
Patients N (%) 
 
Providers N (%) 
    
Gender Male 12 (32%) 1 (11%) 
 Female 25 (68%) 8 (89%) 
    
Race White 15 (41%) 7 (78%) 
 Black 17 (46%) 1 (11%) 
 American Indian 1   (2.5%)  
 Other 3   (8%)  
 Don’t know/Refused 1   (2.5%)  
 Asian  1 (11%) 
    
Education Some high school or 
less 
14 (38%)  
 High school/GED 11 (30%)  
 Some college/technical 
or business school 
10 (27%)  
 College degree or 
above 
2 (5%)  
 MD  8 (89%) 
 PA (Physician Assistant)  1 (11%) 
Employment Employed 6 (16%) 9 (100%) 
 Not employed 3 (8%)  
 Retired 7 (19%)  
 Unable to work 20 (54%)  
 Other/refused 1 (3%)  
Income Comfortable 4 (11%)  
 Just enough 16 (43%)  
 Not enough 16 (43%)  
 Refused to answer 1 (3%)  
    
Mean Age  58 45 
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Highlights 
• Clinical communication about opioid tapering is challenging. 
• Patients need to understand how tapering benefits them individually. 
• Patients want to have input into the tapering process. 
• Patients need to know that their providers will not abandon them during tapering. 
• Provider training should focus on optimal framing of tapering discussions. 
